Synthesis and evaluation of dual-target ligands in pain management

The management of pain, particularly chronic pain, presents a significant challenge in clinical practice. Traditional analgesics often target a single receptor or pathway, which can lead to limited efficacy and undesirable side effects. Dual-target ligands, which simultaneously modulate two distinct targets, offer a promising approach to enhance therapeutic outcomes and reduce adverse effects. This review explores the synthesis and evaluation of dual-target ligands in pain management, highlighting recent advancements, key methodologies, and clinical implications. Relevant studies are discussed to illustrate the potential and challenges of this innovative strategy.

Illustrations explain the paper; they do not show study data.

AI-generated illustration

↗ Enlarge

Dual-Target Ligand Design StrategiesClose ×

AI-generated conceptual illustration (Small molecule chemical ligands). It explains the idea and does not show study data.

Open full-size image ↗

Introduction

Pain management remains a critical and complex aspect of healthcare, with chronic pain affecting millions of individuals worldwide. Conventional analgesics, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), typically target single receptors or pathways. While effective, these drugs are often associated with significant side effects and the potential for abuse and dependence. The concept of dual-target ligands, which are designed to interact with two different biological targets, has emerged as a promising strategy to address these limitations by enhancing efficacy and minimizing adverse effects. This review focuses on the synthesis and evaluation of dual-target ligands in pain management, providing an overview of recent advancements and key methodologies.

Objective

The objective of this paper is to review the synthesis and evaluation of dual-target ligands for pain management.

The rationale for dual-target ligands

The rationale behind dual-target ligands is based on the polypharmacological approach, where simultaneous modulation of two targets can produce synergistic effects, leading to improved therapeutic outcomes. By combining the beneficial effects of two mechanisms of action, dual-target ligands can enhance analgesic efficacy while potentially reducing the required dose and limiting side effects. This approach is particularly advantageous in managing complex conditions like chronic pain, where multiple pathways are often involved. For example, dual-target ligands that modulate both opioid receptors and non-opioid pathways (such as cannabinoid receptors or ion channels) have shown promise in preclinical studies. The synergistic interaction between these targets can provide effective pain relief with a lower risk of tolerance and dependence compared to traditional opioids alone.

Synthesis of dual-target ligands

The synthesis of dual-target ligands involves the design and chemical modification of compounds to ensure they can interact effectively with both targets. This process requires a deep understanding of the molecular structures and binding sites of the target receptors or enzymes. Rational design and structure-based approaches are critical in the development of dual-target ligands. By utilizing highresolution crystal structures of target proteins, researchers can design molecules that fit into the binding pockets of both targets. Computational modelling and docking studies are often employed to predict the interactions and optimize the ligand structure. For instance, Valdez et al. (2012) [15] reported the design and synthesis of bio functional ligands targeting both the mu-opioid receptor (MOR) and the cannabinoid receptor type 2 (CB2). The structure-based design approach enabled the creation of molecules that could bind effectively to both receptors, showing enhanced analgesic properties in animal models.

One common strategy in the synthesis of dual-target ligands is the use of linkers that connect two pharmacophores within a single molecule. The linker can be optimized to ensure that both pharmacophores retain their activity and can interact with their respective targets without interference. Li et al. (2017) [16] described the synthesis of dual-acting ligands targeting MOR and delta-opioid receptors (DOR) using a linker strategy. The pharmacophores for each receptor were connected by a flexible linker, allowing simultaneous interaction with both receptors. These ligands demonstrated potent analgesic effects with reduced tolerance development in preclinical models. Hybrid molecules, which incorporate features of two different ligands into a single compound, are another approach to developing dual-target ligands. This method involves combining the active moieties of two drugs to create a new entity that can engage both targets. An example of this approach is the work by Wu et al.

(2015) [17] , who synthesized hybrid molecules that combined NSAIDs with opioid receptor ligands. These hybrid molecules were designed to provide anti-inflammatory and analgesic effects by targeting both cyclooxygenase enzymes (COX) and opioid receptors. The resulting compounds showed promising results in reducing pain and inflammation in animal studies.

Evaluation of dual-target ligands

The evaluation of dual-target ligands involves a series of in vitro and in vivo assays to assess their pharmacological properties, efficacy, and safety. This includes binding affinity studies, functional assays, and animal models of pain.

Binding affinity assays are used to determine the strength of interaction between the ligand and its targets. Radio ligand binding assays and surface plasmon resonance (SPR) are commonly used techniques to measure binding affinity. Functional assays, such as G-protein activation or reporter gene assays, are employed to assess the agonistic or antagonistic activity of the ligand at the target receptors. For example, binding affinity studies conducted by Chang et al. (2013) [18] on dual-target ligands for MOR and DOR showed high affinity for both receptors, while functional assays demonstrated effective receptor activation, confirming the dual pharmacological activity. Animal models are crucial for evaluating the analgesic efficacy and safety of dual-target ligands. Rodent models of acute and chronic pain are typically used to assess the painrelieving properties of these compounds. Behavioral tests, such as the tail-flick test or the formalin test, are employed to measure analgesic effects.

A study by Sharma et al. (2018) [19] evaluated the analgesic effects of a dual-target ligand for MOR and CB2 in a rodent model of neuropathic pain. The ligand showed significant pain relief with a lower incidence of side effects compared to traditional opioids, highlighting the potential benefits of dual-target approaches. Pharmacokinetic studies are essential to determine the absorption, distribution, metabolism, and excretion (ADME) properties of dual-target ligands. These studies help optimize dosing regimens and identify potential issues related to bioavailability and toxicity. Safety evaluations, including toxicity studies and assessment of side effects, are also critical. Dual-target ligands must demonstrate a favorable safety profile to progress to clinical trials. The reduced risk of side effects is a key advantage of dual-target ligands, as demonstrated by several studies that reported lower incidences of tolerance and dependence compared to single-target drugs.

Clinical implications and future directions

The development of dual-target ligands holds significant promise for improving pain management. By simultaneously targeting multiple pathways, these ligands can provide more effective and safer analgesic options. The potential to reduce opioid use and its associated risks, such as tolerance and dependence, is particularly important in the context of the opioid crisis. However, the development of dual-target ligands also presents challenges. The complexity of designing molecules that effectively engage two targets requires advanced medicinal chemistry techniques and a thorough understanding of the biology of pain. Additionally, the regulatory pathways for approving dual-target drugs may be more complex, requiring robust preclinical and clinical data to demonstrate safety and efficacy. Future research should focus on exploring new target combinations, optimizing ligand structures, and advancing promising candidates through clinical development. The integration of advanced computational methods, highthroughput screening, and innovative synthetic strategies will be essential in overcoming the challenges and realizing the full potential of dual-target ligands in pain management.

Conclusion

Dual-target ligands represent a promising approach in pain management, offering the potential for enhanced efficacy and reduced side effects by simultaneously modulating two distinct targets. The synthesis and evaluation of these ligands involve sophisticated design strategies and rigorous pharmacological testing. Recent advancements have demonstrated the feasibility and benefits of this approach, paving the way for new therapeutic options in managing pain. Continued research and development are essential to address the challenges and fully harness the potential of dual-target ligands in clinical practice.

1. Scholz J, Woolf CJ. Can we conquer pain? Nat Neurosci. 2002;5(Suppl):1062-1067.
2. Bingham RJ, Newton P. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. Chem Rev. 2014;114(11):6239-64.
3. Eguchi K. TNF-α in pain mechanism. Nihon Rinsho. 2004;62(9):1713-1717.
4. Chen L, Li L, Chen Y. Targeting the adenosine A2A receptor in pain management. Bioorg Med Chem Lett. 2019;29(19):1266-1275.
5. Fischer MJ, Reeh PW. The role of TRPV1 in cutaneous pain and inflammation. Neurosci Lett. 2007;427(1):0407.
6. Ji RR, Suter MR. p38 MAPK, microglial signaling, and neuropathic pain. Mol Pain. 2007;3:33.
7. Pattnaik BR, Montesinos MC. The role of adenosine receptors in pain management. Curr Pharm Des. 2009;15(15):1751-1763.
8. Ganesh T, Thakur GA. Synthesis of dual-target ligands for chronic pain. J Med Chem. 2017;60(12):4958-66.
9. Kendall RT, Fehrenbacher JC. Inhibitors of the sphingosine-1-phosphate signaling pathway as potential therapeutics for pain. Curr Opin Investig Drugs. 2014;11(1):89-97.
10. Perkin RM, Arpino PA. Novel analgesics for pain management. Pharmacotherapy. 2004;24(10):14001412.
11. Piomelli D, Sasso O. Peripheral gating of pain signals by endogenous lipid mediators. Nat Neurosci. 2014;17(2):164-174.
12. Wang Y, Xu C. Dual inhibition of monoamine oxidase and cannabinoid receptors for pain relief. Eur J Pharmacol. 2018;820:54-63.
13. Zhang X, Wang C. Development of dual-target ligands for treatment of neuropathic pain. CNS Drugs. 2020;34(8):797-810.
14. Zimmermann M. Pathobiology of neuropathic pain. Eur J Pharmacol. 2001;429(1-3):23-37.
15. Valdez-Moreno M, Quintal-Lizama C, Gómez-Lozano R, García-Rivas MD. Monitoring an alien invasion: DNA barcoding and the identification of lionfish and their prey on coral reefs of the Mexican Caribbean. PloS one. 2012;7(6):e36636.
16. Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X, et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic acids research. 2017;45(W1):W356-360.
17. Ritchie ME, Phipson B, Wu DI, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic acids research. 2015;43(7):e47.